NCT02879695 2026-05-29Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic LeukemiaNational Cancer Institute (NCI)Phase 1 Active not recruiting28 enrolled 16 charts